Advertisement

Tumor Biology

, Volume 35, Issue 2, pp 1169–1175 | Cite as

The role of Bax and Bcl-2 in gemcitabine-mediated cytotoxicity in uveal melanoma cells

  • Jing Wang
  • Renbing Jia
  • Yidan Zhang
  • Xiaofang Xu
  • Xin Song
  • Yixiong Zhou
  • He Zhang
  • Shengfang Ge
  • Xianqun Fan
Research Article

Abstract

Gemcitabine (GEM), a new cytotoxic agent, was shown to be effective against uveal melanoma (UM) which is noted for its resistance to chemotherapy. In this study, we found the different sensitivities to GEM in UM cell lines and identified apoptotic cell death as the cause of GEM cytotoxicity. Both UM cell lines showed an increase in Bax protein levels and activation of cleaved Caspase 3. Additionally, SP6.5 cells showed a gradual increase in Bcl-2 expression over time, whereas VUP cells showed almost none. After interfering in the expression of Bcl-2, the sensitivity to GEM was obviously enhanced in SP6.5 cells. These results suggest that an increase in Bax plays a crucial role in apoptotic cell death induced by GEM in the absence of p53. Moreover, inhibition of Bcl-2 expression can efficiently enhance the cytotoxic effect of, and sensitivity to, GEM in UM cells.

Keywords

Uveal melanoma Bcl-2 Bax Gemcitabine 

Notes

Acknowledgments

This work was supported by the National Natural Science Foundation of China grant (81100683, 81372469, 81372909), the Science and Technology Commission of Shanghai (13ZR1423600, 12ZR1417300) and the Shanghai PuJiang Program (13PJ1405700).

Conflicts of interest

None

References

  1. 1.
    Egan KM. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol. 1988;32:239–51.PubMedCrossRefGoogle Scholar
  2. 2.
    Zoli W. Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro. Clin Cancer Res. 2004;10(4):1500–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Ramanathan RK. Chemotherapy for advanced non-small cell lung cancer: past, present and future. Semin Oncol. 1997;24:440–54.PubMedGoogle Scholar
  4. 4.
    Yamagishi Y. Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma. J Gastroenterol. 2010;45(11):1146–54.PubMedCrossRefGoogle Scholar
  5. 5.
    Neale MH. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer. 1999;79:1487–93.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Schmittel A. A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann Oncol. 2006;17(12):1826–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Atzpodien J. Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients. Cancer Chemother Pharmacol. 2008;62(4):685–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Ruiz van Haperen VW. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol. 1993;46:762–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Plunkett W. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995;22(4 Suppl 11):3–10.PubMedGoogle Scholar
  10. 10.
    Chen M. The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization. Cancer Chemother Pharmacol. 2000;45(5):369–74.PubMedCrossRefGoogle Scholar
  11. 11.
    Galmarini CM. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer. 2002;97(4):439–45.PubMedCrossRefGoogle Scholar
  12. 12.
    Zhou Y. Radiation-inducible human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy: a novel treatment for radioresistant uveal melanoma. Pigment Cell Melanoma Res. 2010;23(5):661–74.PubMedCrossRefGoogle Scholar
  13. 13.
    Cun B. Cell growth inhibition in HPV 18 positive uveal melanoma cells by E6/E7 siRNA. Tumour Biol. 2013;34(3):1801–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Zhang Y. Targeted silencing of MART-1 gene expression by RNA interference enhances the migration ability of uveal melanoma cells. Int J Mol Sci. 2013;14(4):15092–104.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Zhang H. Enhanced therapeutic efficacy by simultaneously targeting two genetic defects in tumors. Mol Ther. 2009;17(1):57–64.PubMedCrossRefGoogle Scholar
  16. 16.
    Wang J. Differential expression of Mart-1 in human uveal melanoma cells. Mol Med Rep. 2011;4(5):799–803.PubMedGoogle Scholar
  17. 17.
    Xu X. Microarray-based analysis: identification of hypoxia-regulated microRNAs in retinoblastoma cells. Int J Oncol. 2011;38(5):1385–93.PubMedGoogle Scholar
  18. 18.
    Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358(6381):15–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Kastan MB. P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev. 1995;14:3–15.PubMedCrossRefGoogle Scholar
  20. 20.
    Huang X. Therapeutic efficacy by targeting correction of Notch1-induced aberrants in uveal tumors. PLoS One. 2012;7(8):e44301.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Huang X. Recombinant oncolytic adenovirus H101 combined with siBCL2: cytotoxic effect on uveal melanoma cell lines. Br J Ophthalmol. 2012;96:1331–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Brady HJ. T cells from bax α transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage-induced cell death in the absence of p53. EMBO J. 1996;15(6):1221–30.PubMedGoogle Scholar
  23. 23.
    Oltvai Z. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609–19.PubMedCrossRefGoogle Scholar
  24. 24.
    Zhang J. Targeted knockdown of Bcl2 in tumor cells using a synthetic TRAIL 3′-UTR microRNA. Int J Cancer. 2010;126(9):2229–39.PubMedCentralPubMedGoogle Scholar
  25. 25.
    Chang GC. Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol. 2004;502(3):169–83.PubMedCrossRefGoogle Scholar
  26. 26.
    Yao Y. Enhanced therapeutic efficacy of vitamin K2 by silencing BCL-2 expression in SMMC-7721 hepatocellular carcinoma cells. Oncol Lett. 2012;4(1):163–7.PubMedCentralPubMedGoogle Scholar
  27. 27.
    White E. Life, death, and the pursuit of apoptosis. Genes Dev. 1996;10(1):1–15.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Jing Wang
    • 1
  • Renbing Jia
    • 1
  • Yidan Zhang
    • 1
  • Xiaofang Xu
    • 1
  • Xin Song
    • 1
  • Yixiong Zhou
    • 1
  • He Zhang
    • 1
  • Shengfang Ge
    • 1
  • Xianqun Fan
    • 1
  1. 1.Department of Ophthalmology, Ninth People’s HospitalShanghai Jiaotong University School of MedicineShanghaiChina

Personalised recommendations